AKTX Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 506.06%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1939.08%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Akari Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Akari Therapeutics PLC.

Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Akari Therapeutics PLC's net income of -$3.7M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 0.92x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of -170.14%. Akari Therapeutics PLC's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 506.06%. On the other hand Cellectis SA has an analysts' consensus of $5.75 which suggests that it could grow by 248.49%. Given that Akari Therapeutics PLC has higher upside potential than Cellectis SA, analysts believe Akari Therapeutics PLC is more attractive than Cellectis SA.

Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.910, suggesting its more volatile than the S&P 500 by 191%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.7M. Akari Therapeutics PLC's net income of -$3.7M is higher than Cellectis SA's net income of -$18.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 3.38x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.

Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 506.06%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 55.89%. Given that Akari Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics PLC is more attractive than DBV Technologies SA.

Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Akari Therapeutics PLC's net income of -$3.7M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat NuCana PLC's return on equity of --.

Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 506.06%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 183970.8%. Given that NuCana PLC has higher upside potential than Akari Therapeutics PLC, analysts believe NuCana PLC is more attractive than Akari Therapeutics PLC.

Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Akari Therapeutics PLC's net income of -$3.7M is lower than NuCana PLC's net income of -$3.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.